Lake Street raised the firm’s price target on ClearPoint Neuro (CLPT) to $17 from $15 and keeps a Buy rating on the shares. Q3 outperformance was driven by another quarter of broad-business strength, says the firm, which tells investors that “the business has significant growth momentum, expectations are in check, profitability is improving, and the balance sheet is solid.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks